Deva Holdings

Founded in 1958, Deva Holdings has grown from a domestic Turkish pharmaceutical player into an internationally recognized, publicly traded generics and API manufacturer. Its strategy is built on vertical integration, a strong R&D focus on bioequivalence, and geographic expansion into over 80 countries. Key achievements include establishing a significant export business, maintaining a diverse portfolio spanning multiple therapeutic areas, and operating a large-scale, end-to-end production infrastructure. The company's mission, 'For lives we add health to...', underscores its commercial focus on affordable, accessible medicine.

Vertically integrated platform focused on the development and manufacturing of bioequivalent generic small molecules and APIs, with capabilities extending into biotechnology for complex generics and biosimilars.

Deva competes domestically with other major Turkish pharma firms (e.g., Abdi İbrahim, Nobel) and internationally with global generics giants (e.g., Teva, Sandoz) and low-cost regional producers. Its vertical integration and strong domestic base are primary differentiators in a crowded, price-sensitive market.